<DOC>
	<DOCNO>NCT02480712</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety tolerability sofosbuvir ( SOF ) /velpatasvir ( VEL ; GS-5816 ) fix dose combination ( FDC ) administer 12 week HCV treatment-naive treatment-experienced ( include treatment intolerant ) adult chronic HCV infection coinfected HIV-1 .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir/Velpatasvir Fixed Dose Combination 12 Weeks Adults With Chronic Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) -1 Coinfection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCV RNA â‰¥ 10^4 IU/mL screen HCV genotype 1 , 2 , 3 , 4 , 5 , 6 Cirrhosis determination , fibroscan liver biopsy may require HIV1 infection Use protocol specify method ( ) contraception Screening laboratory value within define threshold Clinicallysignificant illness ( HCV HIV ) major medical disorder may interfere individual 's treatment , assessment compliance protocol Current prior history clinical hepatic decompensation , hepatocellular carcinoma ( HCC ) malignancy ( exception certain resolve skin cancer ) Screening ECG clinically significant abnormality Pregnant nurse female male pregnant female partner Infection hepatitis B virus ( HBV ) Use prohibit concomitant medication describe protocol Chronic use systemically administer immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>